Market name for BPC-157 and TB-500 sold in one vial for injury recovery, the pairing being justified by two unrelated proposed mechanisms — VEGF upregulation and nitric-oxide pathway modulation for the pentadecapeptide, G-actin sequestration and cell migration for the thymosin fragment. The name is a nickname rather than an acronym, and the combination has essentially no evidence: the one controlled animal test of the pair found no additive benefit over either peptide alone.
Vendor-defined. Research vendors state 1:1 by mass (10 mg + 10 mg, or 5 + 5, per vial); compounding pharmacies use 1:2.
COMPOSITION IS FROM VENDOR PAGES, NAMED AS SUCH, because there is no other source. The 1:1 split is stated consistently — royal-peptides.com "Each vial contains a total of 20 mg of research material: 10 mg BPC-157 and 10 mg TB-500", oathresearch.com "BPC-157 (5mg) and TB-500 (5mg) in a balanced 1:1 ratio, totaling 10mg", pspeptides.com "10mg BPC-157 + 10mg TB-500 (20mg vial) or 5mg + 5mg (10mg vial)", plus americanpeptides.us and prohealthsolutionsfl.com. A COMPOUNDED ROUTE DIVERGES: moonshotmp.com states "roughly 5mg BPC-157 and 10mg TB-500 per vial", i.e. 1:2, so a user's actual ratio depends on where it came from. THE DOSE BLOCK IS EMPTY ON PURPOSE. Every source states a VIAL TOTAL, not a per-injection amount; a vial is reconstituted and split across many doses, so storing 20 mg as a dose would overstate a single administration by an order of magnitude. EVIDENCE FOR THE COMBINATION, such as it is: PMID:42542926 is the only controlled test, a rat Achilles model with four arms including "combined BPC-157 + TB-500", administered intraperitoneally for four weeks at 10 and 60 micrograms/kg/day — a 1:6 ratio, not the vendor 1:1 — and its finding is negative, "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone". PMID:34324435 is a retrospective chart review in which "The other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4", uncontrolled, with "No specific tools ... used to measure their improvement" and separate injections rather than a blend. No indexed paper studies a branded blend or a vendor ratio, and "Wolverine" never appears in PubMed beside these peptides.